Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled “분기보고서 (제 73 기) 2026년 01월 01일~2026년 03월 31일” for Samsung Pharm Co., covering actual financials, business overview, segment data, product sales, raw materials, and detailed schedules. It is a full quarterly report containing substantive financial tables and narrative, not merely an announcement or certification. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
소송등의판결ㆍ결정(일정금액이상의청구)
Regulatory Filings
2026-05-08 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “정기주주총회결과” (Annual General Meeting Results) and details voting outcomes for each agenda item (approval of financial statements, board appointments, changes in articles, remuneration limits, etc.). It lists vote counts, percentages, and resolutions passed. This matches an official Declaration of Voting Results from a shareholder meeting. Therefore, it is classified as DVA.
2026-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 90% confidence The document is a Korean regulatory filing titled "사외이사의 선임·해임 또는 중도퇴임에 관한 신고", detailing the appointment, dismissal, and resignation of outside directors. It reports changes to the board of directors, including names, terms, and qualifications. This matches the definition of a Board/Management Information announcement (Code: MANG).
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Samsung Pharmaceutical Co., Ltd. It includes the independent auditor's report, full financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements for the fiscal year ending December 31, 2025. Since it contains the full set of audited financial statements and is not merely an announcement or a summary, it is classified as an Annual Report (10-K) equivalent in the context of financial reporting standards. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) by Samsung Pharmaceutical. It provides a summary of the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit/loss), and the name of the auditor. It is a regulatory filing announcing the completion and submission of the audit report to the exchange, rather than the full audit report document itself. According to the 'Menu vs Meal' rule, this is a report publication announcement. FY 2025
2026-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.